e-learning
resources
Munich 2014
Sunday, 07.09.2014
New treatments for cough, asthma, COPD and ILDs
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage
O. Enikeev, S. Enikeeva, N.R. Bikmetova (Ufa, Russian Federation)
Source:
International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Session:
New treatments for cough, asthma, COPD and ILDs
Session type:
Poster Discussion
Number:
1514
Disease area:
Airway diseases
Abstract
Aim: To study the influence of the therapy PPAR-alpha agonist (fenofibrate) in exacerbation dynamics of severe stage of chronic obstructive pulmonary disease (AECOPD) patients. Methods: Peripheral blood samples were collected from 20 patients with severe AECOPD receiving conventional therapy with 145 mg fenofibrate (1 tablet once a day No. 10) and 21 patients with severe AECOPD and 20 man from control group. Lymphocytes were isolated by two-color labeled monoclonal antibodies flow cytometry to examine the quantities and percentage of, CD3+CD19- T cell, CD3-CD19+ B cell, CD3+CD4+ T cell, CD3+CD8+ T cell, respectively. Enzyme immunodetection was used to detect the expression of tumor necrosis factor
a
(TNF-
a
). All patients underwent a spirography with broncholytic breakdown. Mann-Whitney test was used for comparison between data before and after treatment an control group. Results: Complex therapy with inclusion of fenofibrate significantly increased the indicators of TNF-a, compared with conventional therapy (p<0.05). This increase was accompanied by a significant increase in levels of FVC, FEV1/FVC, MEF75, MEF 25 and VC MAX, compared with the group receiving conventional therapy (p<0.05). Conclusion: Fenofibrate in addition to the direct immunomodulating effect, significantly improves the function of external respiration. Statistically significant increase in the level of TNF-alpha may be associated with activation of apoptosis phagocytic cells, leading to the limitation of the systemic inflammatory response in the body.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Enikeev, S. Enikeeva, N.R. Bikmetova (Ufa, Russian Federation). PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage. Eur Respir J 2014; 44: Suppl. 58, 1514
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Long term treatment with n-acetylcysteine reduces exacerbations in moderate chronic obstructive pulmonary disease
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
Effects of pulmonary rehabilitation on exacerbation number and severity in people with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Survivin in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
Source: International Congress 2014 – Comorbidities
Year: 2014
Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 903-908
Year: 2001
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Current maintenance treatment of chronic obstructive pulmonary disease in China
Source: International Congress 2014 – Respiratory disease within hospital-based populations
Year: 2014
Modulation of airway inflammation to prevent exacerbations of COPD
Source: Eur Respir Rev 2005; 14: 78-82
Year: 2005
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
Dynamics of sputum antimicrobial peptide levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
Oscillating positive expiratory pressure (oPEP) therapy in chronic obstructive pulmonary disease and bronchiectasis
Source: International Congress 2014 – Best posters in chronic care
Year: 2014
Clinical evaluation of a new inhibitor of neutrophilic inflammation, tetomilast (OPC-6535), in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept